-transparent.png){kind=logo}
The live Edmonston-Zagreb measles vaccine is currently produced either on chick-embryo fibroblasts (CEF) or on human diploid cells (HDC). Its stability meets the WHO requirements. Since the vaccine licensure in 1967 the Edmonston-Zagreb measles virus strain has been administered to over 20 million vaccinees either as a monovalent vaccine or as a component of the combined MR, MMR and MM vaccines. Immunogenicity studies have shown the persistence of the elicited HI antibody for a minimum of 16 years. In children aged 13-17 months a greater than 95% seroconversion was recorded after subcutaneous administration both CEF and HDC vaccines. The vaccine has also been shown to be highly immunogenic when administered intranasally. In 6-12 month old infants the Edmonston-Zagreb monovalent vaccine elicited a 100% HI antibody response after both s.c. and i.n. administration. The GMT of antibody 42 days after vaccination was significantly higher in those given HDC vaccine, regardless of the age of the vaccinees or the route of immunization.
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
January 1983,
Reviews of infectious diseases,
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
October 1996,
Indian pediatrics,
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
August 1994,
Lancet (London, England),
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
January 1972,
Annales immunologiae Hungaricae,
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
September 1987,
The Pediatric infectious disease journal,
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
November 1999,
Pediatrics,
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
January 2021,
Allergologia et immunopathologia,
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
June 1996,
The Journal of infectious diseases,
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
October 1988,
Lancet (London, England),
M Beck, and
S Smerdel, and
I Dedić, and
N Delimar, and
M Rajninger-Miholic, and
M Juzbasić, and
T Manhalter, and
R Vlatković, and
B Borcić, and
Z Mihajić
October 1990,
Lancet (London, England),
